Six psychotropics for pre-symptomatic & early Alzheimer’s (MCI), Parkinson’s, and Huntington’s disease modiifcation
Edward C. Lauterbach
摘要：The quest for neuroprotective drugs to slow the progression of neurodegenerative diseases (NDDs), includ-ing Alzheimer’s disease (AD), Parkinson’s disease (PD), and Huntington’s disease (HD), has been largely unrewarding. Preclinical evidence suggests that repurposing quetiapine, lithium, valproate, fluoxetine, donepezil, and memantine for early and pre-symptomatic disease-modiifcation in NDDs may be promising and can spare regulatory barriers. The literature of these psychotropics in early stage and pre-symptomatic AD, PD, and HD is reviewed and propitious ifndings follow. Mild cognitive impairment (MCI) phase of AD: salutary human randomized controlled trial ifndings for low-dose lithium and, in selected patients, donepezil await replication. Pre-symptomatic AD: human epidemiological data indicate that lithium reduc-es AD risk. Animal model studies (AMS) reveal encouraging results for quetiapine, lithium, donepezil, and memantine. Early PD: valproate AMS ifndings show promise. Pre-symptomatic PD: lithium and valproate AMS ifndings are encouraging. Early HD: uncontrolled clinical data indicate non-progression with lithium, lfuoxetine, donepezil, and memantine. Pre-symptomatic HD: lithium and valproate are auspicious in AMS. Many other promising ifndings awaiting replication (valproate in MCI; lithium, valproate, lfuoxetine in pre-symptomatic AD; lithium in early PD; lithium, valproate, lfuoxetine in pre-symptomatic PD; donepezil in early HD; lithium, lfuoxetine, memantine in pre-symptomatic HD) are reviewed. Dose- and stage-de-pendent effects are considered. Suggestions for signal-enhancement in human trials are provided for each NDD stage.
机标关键词：randomized controlled trialneurodegenerative diseases
论文发表日期：2016-01-01
在线出版日期：2025-08-15（本平台首次上网日期，不代表文献的发表时间）
页数：15( 1712-1726 )
英文信息